Maxim Group set a $25.00 price objective on Aridis Pharmaceuticals (NASDAQ:ARDS) in a research note released on Wednesday morning. The brokerage currently has a buy rating on the stock.

“Aridis announced that the first subject has been enrolled in its P1/2a study evaluating AR-501 for the treatment of chronic bacterial lung infections in patients with cystic fibrosis (CF).”,” Maxim Group’s analyst commented.

A number of other research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Aridis Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, November 20th. Cantor Fitzgerald reaffirmed a buy rating and issued a $25.00 price target on shares of Aridis Pharmaceuticals in a report on Tuesday, November 13th. Northcoast Research began coverage on shares of Aridis Pharmaceuticals in a report on Monday, September 10th. They issued an outperform rating and a $40.00 price target for the company. Northland Securities began coverage on shares of Aridis Pharmaceuticals in a report on Monday, September 10th. They issued an outperform rating for the company. Finally, Laidlaw began coverage on shares of Aridis Pharmaceuticals in a report on Monday, September 10th. They issued a buy rating and a $23.00 price target for the company. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $25.40.

Shares of NASDAQ ARDS traded up $0.26 during midday trading on Wednesday, reaching $9.26. The company had a trading volume of 2,629 shares, compared to its average volume of 5,575. Aridis Pharmaceuticals has a 1 year low of $7.59 and a 1 year high of $13.85.

Aridis Pharmaceuticals (NASDAQ:ARDS) last posted its quarterly earnings results on Tuesday, November 13th. The company reported ($1.97) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.92). The business had revenue of $1.02 million for the quarter, compared to analyst estimates of $0.33 million. As a group, equities analysts anticipate that Aridis Pharmaceuticals will post -3.05 earnings per share for the current year.

Aridis Pharmaceuticals Company Profile

Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L.

Further Reading: What are the economic characteristics of a bear market?

Analyst Recommendations for Aridis Pharmaceuticals (NASDAQ:ARDS)

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.